DBL HEPARIN SODIUM (porcine mucous) 5000IU/0.2 mL injection BP ampoule, Pfizer Australia Pty Ltd, CON-964

The product conforms to the requirements of the British Pharmacopeia 2021 rather than the British Pharmacopeia 2022. The differences between the compendial versions are (i) identification testing using electrophoresis rather than nuclear magnetic resonance spectrometry and (ii) change to the HPLC gradient ratio and change to the limit for any other peak for the Related Substance test a disregard limit of 0.02% corresponding to any other impurity rather than no peaks other than the peak due to dermatan sulfate and chondroitin sulfate are detected.